Yahoo Web Search

Search results

1. • FDA approves 2 Eylea biosimilars

     Becker’s Hospital Review· 20 hours ago

     The FDA granted approval to Biocon Biologics' drug Yesafili and Samsung Bioepis and Biogen's drug Opuviz, the agency announced May 20. The two drugs are biosimilars for Eylea, an injection made ...

2. • 

     Ocugen completes second cohort dosing in Stargardt trial By Investing.com

     Investing.com· 5 days ago

     The trial represents a potential breakthrough for patients with this inherited retinal disease,...

3. • Foundation Fighting Blindness to Host VISIONS 2024 Conference

     WFRV 5 Green Bay· 4 days ago

     ...PRNewswire/ -- The Foundation Fighting Blindness, the driving force in the global development of treatments and cures for blinding diseases, will host its VISIONS 2024 conference at the Chicago Marriott Downtown...diseases such as retinitis pigmentosa, Usher syndrome, Stargardt disease, Leber...

4. • 

     7 Biotech Stocks That Could Breathe New Life Into Your Portfolio

     InvestorPlace· 9 hours ago

     Fundamentally, one of the biggest advantages of biotech stocks to buy centers on the underlying...

5. • Q1 2024 Ocugen Inc Earnings Call

     Thomson Reuters StreetEvents via Yahoo Finance· 6 days ago

     To better understand the experience of one of our Phase 1/2 clinical trial patients, I encourage you to watch this video and the patient's section of our website. Moving on to our development ...

6. • Small Business - Picayune Item | Picayune Item

     The Picayune Item· 7 days ago

     Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related ...

7. • 

     These 2 No-Brainer Growth Stocks Are Breaking New Ground

     Motley Fool via Yahoo Finance· 5 days ago

     Excluding its COVID-19 antibody, Regeneron's revenue increased by 7%. Eylea treats wet age-related ...

8. • Chardan Capital Weighs in on Ocugen, Inc.’s FY2024 Earnings (NASDAQ:OCGN)

     ETF DAILY NEWS· 24 hours ago

     Ocugen, Inc. (NASDAQ:OCGN – Free Report) – Chardan Capital boosted their FY2024 earnings per share (EPS) estimates for Ocugen in a research note issued on Wednesday, May 15th. Chardan Capital ...

9. • Ranibizumab is safe for treating retinopathy of prematurity

     UB Reporter· 6 days ago

     For several decades, laser therapy has been the primary treatment method for ROP. Laser treatment involves burning the infant’s peripheral retina to stop ...

10. • Foundation Fighting Blindness Partners with Preven | Newswise

      Newswise· 6 days ago

      COLUMBIA, Md., May 15, 2024 /PRNewswire/ -- The Foundation Fighting Blindness, the driving force in the global development of treatments and cures for blinding diseases, announces ...